Sanofi SA and Regeneron Pharmaceuticals Inc's ZALTRAP Receive Marketing Authorization from European Union

Tuesday, 5 Feb 2013 01:05am EST 

Sanofi SA announced that with Regeneron Pharmaceuticals Inc the European Commission (EC) has granted marketing authorization in the European Union for ZALTRAP 25mg/ml concentrate for solution for infusion in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy in adults with metastatic colorectal cancer (mCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen. This decision was based on the efficacy and safety results of the VELOUR Phase 3 trial. 

Company Quote

0.26 +0.34%
23 Dec 2014